Bristol Melanoma Drug's Advisory Panel Delayed Following Review Date Delay
This article was originally published in The Pink Sheet Daily
Additional Phase III data for ipilimumab might be available by next year, and an early March advisory committee date now looks likely, given the rescheduled PDUFA date of March 26, 2011.
You may also be interested in...
After missing the boat in non-small cell lung cancer, AstraZeneca has repositioned the drug for the rare advanced medullary thyroid cancer.
Panelists may want to wait for results from a second Phase III trial and, given severe side effects, are likely to want a robust risk management plan.
If approved, the CTLA-4 inhibitor would be the first new drug for the treatment of metastatic melanoma in over a decade.